logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5569.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5569.produseast1
Advancing Research to Improve NTD Treatments in Children by Saschveen Singh | Collections | MSF Science Portal
Advancing Research to Improve NTD Treatments in Children by Saschveen Singh

Advancing Research to Improve NTD Treatments in Children by Saschveen Singh

Dr. Saschveen Singh is a tropical infectious disease advisor for MSF. Read more of MSF's recent work on neglected tropical diseases in pediatric populations, and of Dr. Singh's work at MSF.

Collection Content

Journal Article
|
Protocol

Host, parasite and drug determinants of clinical outcomes following treatment of visceral leishmaniasis: a protocol for individual participant data meta-analysis

Kumar R, Dahal P, Singh-Phulgenda S, Siddiqui NA, Munir A,  et al.
2023-10-28 • BMJ Open
2023-10-28 • BMJ Open
INTRODUCTION
Visceral leishmaniasis (VL) is a parasitic disease with an estimated 30 000 new cases occurring annually. There is an observed variation in the efficacy of the current f...
Journal Article
|
Research

Proportion of paediatric admissions with any stage of noma at the Anka General Hospital, northwest Nigeria

Farley ES, Karinja MN, Lawal AM, Olaleye M, Muhammad S,  et al.
2023-10-27 • PLOS Neglected Tropical Diseases
2023-10-27 • PLOS Neglected Tropical Diseases
INTRODUCTION
Noma is a rapidly spreading infection of the oral cavity which mainly affects young children. Without early treatment, it can have a high mortality rate. Simple gingivit...
Journal Article
|
Research

Population pharmacokinetics of a combination of miltefosine and paromomycin in Eastern African children and adults with visceral leishmaniasis

Verrest L, Roseboom IC, Wasunna M, Mbui J, Njenga SN,  et al.
2023-09-20 • Journal of Antimicrobial Chemotherapy
2023-09-20 • Journal of Antimicrobial Chemotherapy
OBJECTIVES
To improve visceral leishmaniasis (VL) treatment in Eastern Africa, 14- and 28-day combination regimens of paromomycin plus allometrically dosed miltefosine were evaluated...
Conference Material
|
Video

Schistosomiasis: A public health problem in young children

Garba Djirmay A
2022-12-01 • MSF Paediatric Days 2022
2022-12-01 • MSF Paediatric Days 2022
Conference Material
|
Video

Raising awareness of noma, a personal journey

Okanlawon M
2022-12-01 • MSF Paediatric Days 2022
2022-12-01 • MSF Paediatric Days 2022
Conference Material
|
Abstract

Noma discharge toolkit - a person-centred approach to improve continuity of care

Ajamah S, Tanaka M, De Vore K, Vogiazou Y, Joseph S,  et al.
2022-11-26 • MSF Paediatric Days 2022
2022-11-26 • MSF Paediatric Days 2022
BACKGROUND AND AIMS
The Noma hospital in Sokoto State, Nigeria, provides specialised care for noma, a rapidly progressive and often fatal necrotising bacterial disease, which continu...
Journal Article
|
Review

Snakebite envenoming in humanitarian crises and migration: A scoping review and the Médecins Sans Frontières experience

Alcoba G, Potet J, Vatrinet R, Singh SN, Nanclares C,  et al.
2022-03-01 • Toxicon: X
2022-03-01 • Toxicon: X
Snakebite envenoming is a public health concern in many countries affected by humanitarian crises. Its magnitude was recognized internationally but associations between snakebite peaks a...
Conference Material
|
Abstract

Validation of a clinical score for the diagnosis of Mycobacterium ulcerans (Buruli Ulcer) infection in Cameroon

Ntone R
2021-06-10 • Epicentre Scientific Day Paris 2021
2021-06-10 • Epicentre Scientific Day Paris 2021
CONTEXT
Early diagnosis of Buruli Ulcer (BU) improves its management and limits any sequelae. However, access to PCR diagnostics remains limited. This study aimed to validate a clini...
Journal Article
|
Commentary

Model of care, Noma Children’s Hospital, northwest Nigeria

Isah S, Amirtharajah M, Farley ES, Adetunji AS, Samuel J,  et al.
2021-06-03 • Tropical Medicine and International Health
2021-06-03 • Tropical Medicine and International Health
The Nigerian Ministry of Health has been offering care for noma patients for many years at the Noma Children's Hospital (NCH) in Sokoto, northwest Nigeria, and Médecins Sans Frontières h...
Journal Article
|
Research

Dengue in Western Uganda: a prospective cohort of children presenting with undifferentiated febrile illness

Boyce RM, Muhindo R, Nakakande R, Ciccone EJ, Grounds S,  et al.
2020-11-11 • BMC Infectious Diseases
2020-11-11 • BMC Infectious Diseases
BACKGROUND
The spatial distribution and burden of dengue in sub-Saharan Africa remains highly uncertain, despite high levels of ecological suitability. The goal of this study was to ...
Journal Article
|
Case Report/Series

Outcomes at 18 mo of 37 noma (cancrum oris) cases surgically treated at the Noma Children's Hospital, Sokoto, Nigeria

Farley ES, Amirtharajah M, Winters RD, Taiwo AO, Oyemakinde MJ,  et al.
2020-08-12 • Transactions of the Royal Society of Tropical Medicine and Hygiene
2020-08-12 • Transactions of the Royal Society of Tropical Medicine and Hygiene
BACKGROUND
Noma is a rapidly progressing infection of the oral cavity frequently resulting in severe facial disfigurement. We present a case series of noma patients surgically treate...
Journal Article
|
Research

Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, India

Goyal V, Mahajan R, Pandey K, Singh SN, Singh RS,  et al.
2018-10-22 • PLOS Neglected Tropical Diseases
2018-10-22 • PLOS Neglected Tropical Diseases
BACKGROUND
In 2010, WHO recommended the use of new short-course treatment regimens in kala-azar elimination efforts for the Indian subcontinent. Although phase 3 studies have shown e...

See more collections

MSF logo
Costs, cost-effectiveness, and financing of tuberculosis trea...

Tuberculosis (TB) is the world's deadliest infectious disease, and the leading killer of people with HIV. TB is curable, but it can be difficult to diagnose and tough to treat, especially for increasingly prevalent drug-resistant TB. In 2023, 22,700 people started TB treatment in MSF programs. Understanding the costs and cost-effectiveness associated with TB treatment and innovations, ranging from TB diagnostics and medications to TB care models, can help to plan resource needs and allocate resources effectively. Analyzing financing mechanisms can support developing sustainable funding models for TB control.

This collection spotlights articles by MSF and collaborators to analyze and document the costs of care, particularly diagnostics and medications.

Neglected tropical diseases in 2023
Neglected tropical diseases in 2023

Each year hundreds of thousands of people die from a neglected tropical disease, while many more suffer serious illness or lifelong disability. Yet as we mark World Neglected Tropical Diseases (NTD) Day on 30th January 2023, global progress towards eliminating these diseases is threatened by shifting global health priorities and declining investment in the wake of the Covid-19 pandemic.


The content collection linked below offers a snapshot of MSF’s work over the past two years on managing some of the most deadly NTDs, finding better tools and models of care for highly affected populations, and advocating for greater access to care and increased global funding. Several authors describe our programs and lessons learned from a decade of treating snakebite victims in sub-Saharan Africa. Two studies evaluate shorter, less toxic treatment for visceral leischmaniasis, while a policy analysis proposes critical steps towards eliminating this horrific disease in East Africa. Last, reports from Sokoto, Nigeria describe the collaborative development of a comprehensive model of care for noma.

Mini-Lab—MSF's simplified bacteriology laboratory for low-resource settings
Mini-Lab—MSF's simplified bacteriology laboratory for low-res...
Resistance to antibiotics is a growing public health crisis, especially in countries with fragile health systems and in regions at war. One key limitation in most of these settings is a lack of clinical bacteriology laboratory capacity, which leaves medical providers without ways to accurately diagnose patient infections and to tailor antibiotic treatment accordingly. To help fill this critical gap, MSF and partners have developed the Mini-Lab—a small-scale, standalone lab that is easy to transport, set up and operate by staff after only a short training. Its six modules are stocked with everything needed to diagnose common bloodstream and urinary tract infections and to perform antibiotic sensitivity testing using methods adapted to extremely hot climates and remote settings. With Mini-Lab now being rolled out to selected MSF projects, here we highlight the background to its development and some of the research behind the bacteriological tests it incorporates.
View All Collections